LV11803B - Nesplaisinga gp350/220 varianti - Google Patents

Nesplaisinga gp350/220 varianti Download PDF

Info

Publication number
LV11803B
LV11803B LVP-96-430A LV960430A LV11803B LV 11803 B LV11803 B LV 11803B LV 960430 A LV960430 A LV 960430A LV 11803 B LV11803 B LV 11803B
Authority
LV
Latvia
Prior art keywords
thr
pro
ser
amino acid
protein
Prior art date
Application number
LVP-96-430A
Other languages
English (en)
Other versions
LV11803A (lv
Inventor
Richard Spaete
Winthrop T. Jackman
Original Assignee
Aviron
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aviron filed Critical Aviron
Publication of LV11803A publication Critical patent/LV11803A/lv
Publication of LV11803B publication Critical patent/LV11803B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Surgical Instruments (AREA)
  • Registering, Tensioning, Guiding Webs, And Rollers Therefor (AREA)

Claims (10)

  1. LV 11803 IZGUDROJUMA FORMULA 1. Izolētā DNS secība, kura kode homogenā gp350 protema ekspresiju.
  2. 2. DNS secība saskaņā ar 1. punktu, kuru papildus raksturo ar nukleotīdu secību, kurā vismaz viens dabīgais nukleotīds, kas kodē serīnu 501. pozīcijā Fig.l., ir aizvietots ar dabā neesošu nukleotīdu, un kurā vismaz viens dabīgais nukleotīds, kas kodē glicīnu 698. pozīcijā , ir aizvietots ar dabā neesošu nukleotīdu.
  3. 3. DNS secība saskaņā ar 1. punktu, kurā minētais homogēnais gp350 proteīns, kuru papildus raksturo ar aminoskābes kodējošo secību, kura atlasīta no grupas, kas kodē aminoskābes no: (a) 19. aminoskābes līdz 862. aminoskābei Fig.l. (b) 1. aminoskābes līdz 862. aminoskābei Fig.l. (c) 19. aminoskābes līdz 862. aminoskābei un 882. aminoskābes līdz 907. aminoskābei Fig.l. (d) 1. aminoskābes līdz 862. aminoskābei un 882. aminoskābes līdz 907. aminoskābei Fig.l. (e) 1. aminoskābes līdz 907. aminoskābei, kurā vismaz 8 transmembrānās zonas aminoskābes kodējošie nukleotīdi ir zaudēti.
  4. 4. Vektors, kurš satur DNS secību saskaņā ar 1. punktu, 2. punktu vai 3. punktu.
  5. 5. Saimniekšūnas, kas transformētas ar DNS secību saskaņā ar 1. punktu, 2. punktu vai 3. punktu operatīvā savienojumā ar ekspresijas kontroles secību, kura spējīga vadīt minētās replicētās DNS secības ekspresiju.
  6. 6. Process homogēnā gp350 proteīna pagatavošanai, kurš ietver saimniekšūnu saskaņā ar 5. punktu kultivēšanu piemērotā kultūras barotnē un minētā homogēnā gp350 proteīna izdalīšanu no minētām šūnām.
  7. 7. Homogēnais gp350 proteīns, pagatavots saskaņā ar procesu, aprakstītu 6. punktā.
  8. 8. Homogēnais gp350 proteīns, kurā viens vai vairāki dabīgie nukleotīdi, kodējošie donora splaisinga saitu un akceptora splaisinga saitu, ir aizvietoti ar aizvietotājnukleotīdu(iem), kas atšķiras no minētā(iem) nukleotīda(iem) un kas pasargā minēto donora un akceptora saitu aminoskābju secību.
  9. 9. Farmaceitiskais sastāvas, kurš satur homogēno gp350 proteīnu saskaņā ar 7. punktu vai 8. punktu maisījumā ar farmaceitiski pieņēmamu pāmesēju.
  10. 10. Homogēnā gp350 proteīna izmantošana farmaceitiskā sastāva pagatavošanai, kurš ir piemērots ar Epšteina-Bāra vīrusu saistītu slimību vai stāvokļu profilaksei.
LVP-96-430A 1994-04-18 1996-11-12 Nesplaisinga gp350/220 varianti LV11803B (lv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22929194A 1994-04-18 1994-04-18
PCT/US1995/004611 WO1995028488A1 (en) 1994-04-18 1995-04-13 NON-SPLICING VARIANTS OF gp350/220

Publications (2)

Publication Number Publication Date
LV11803A LV11803A (lv) 1997-06-20
LV11803B true LV11803B (lv) 1998-01-20

Family

ID=22860582

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-430A LV11803B (lv) 1994-04-18 1996-11-12 Nesplaisinga gp350/220 varianti

Country Status (25)

Country Link
US (3) US6054130A (lv)
EP (1) EP0769056B1 (lv)
JP (4) JP3447743B2 (lv)
KR (1) KR100380953B1 (lv)
CN (2) CN1118573C (lv)
AT (1) ATE210184T1 (lv)
AU (1) AU707837B2 (lv)
BR (1) BR9507473A (lv)
CA (1) CA2187908C (lv)
CZ (1) CZ292283B6 (lv)
DE (1) DE69524415T2 (lv)
DK (1) DK0769056T3 (lv)
ES (1) ES2170144T3 (lv)
FI (2) FI118224B (lv)
HU (1) HU221647B1 (lv)
LV (1) LV11803B (lv)
MY (1) MY114769A (lv)
NO (1) NO319382B1 (lv)
PL (1) PL181881B1 (lv)
PT (1) PT769056E (lv)
RU (1) RU2178807C2 (lv)
SK (1) SK283446B6 (lv)
TW (1) TW496897B (lv)
UA (1) UA47403C2 (lv)
WO (1) WO1995028488A1 (lv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220
US6692749B1 (en) * 1994-04-18 2004-02-17 Medimmune Vaccines, Inc. Non-splicing variants of gp350/220
AU2582897A (en) * 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
AUPO784197A0 (en) * 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
CA2312291A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
AU762799B2 (en) 1998-06-12 2003-07-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Enhancement of B cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and EBV Gp350/220
GB0210682D0 (en) * 2002-05-09 2002-06-19 Glaxosmithkline Biolog Sa Novel use
CA2799995A1 (en) * 2009-05-22 2010-11-25 Intelligent Medical Devices, Inc. Optimized probes and primers and methods of using same for the detection, screening, quantitation, isolation and sequencing of cytomegalovirus and epstein-barr virus
US10461635B1 (en) * 2018-05-15 2019-10-29 Analog Devices Global Unlimited Company Low VIN high efficiency chargepump

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069310D1 (en) * 1980-11-03 1984-10-31 Itt Ind Gmbh Deutsche Binary mos ripple carry parallel adder/subtractor and appropriate adding/subtracting stage
US4707358A (en) * 1984-01-30 1987-11-17 The University Of Chicago Vaccine against Epstein-Barr Virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
EP0173254B1 (en) * 1984-08-23 1991-07-24 Hans Joachim Wolf Dna sequences of the ebv genome, recombinant dna molecules, processes for producing ebv-related antigens, diagnostic compositions and pharmaceutical compositions containing said antigens
EP0312164A1 (en) * 1987-10-16 1989-04-19 Merck & Co. Inc. Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells
CA2090295A1 (en) * 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
AU1648092A (en) * 1992-03-19 1993-10-21 Cancer Research Campaign Technology Limited Defective recombinant adenoviruses expressing characteristic epstein-barr virus proteins
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
MY114769A (en) 1994-04-18 2003-01-31 Aviron Inc Non-splicing variants of gp350/220

Also Published As

Publication number Publication date
DK0769056T3 (da) 2002-04-02
CA2187908C (en) 2002-09-17
ATE210184T1 (de) 2001-12-15
BR9507473A (pt) 1997-09-23
EP0769056A4 (en) 1998-03-04
ES2170144T3 (es) 2002-08-01
HU9602894D0 (en) 1996-12-30
AU2383895A (en) 1995-11-10
PL316941A1 (en) 1997-02-17
CN100415895C (zh) 2008-09-03
FI964186A (fi) 1996-12-17
HUT75831A (en) 1997-05-28
UA47403C2 (uk) 2002-07-15
FI964186A0 (fi) 1996-10-18
SK283446B6 (sk) 2003-07-01
EP0769056A1 (en) 1997-04-23
NO319382B1 (no) 2005-07-25
NO964431D0 (no) 1996-10-18
CN1495262A (zh) 2004-05-12
CN1152940A (zh) 1997-06-25
RU2178807C2 (ru) 2002-01-27
PT769056E (pt) 2002-05-31
CA2187908A1 (en) 1995-10-26
US6458364B1 (en) 2002-10-01
WO1995028488A1 (en) 1995-10-26
JP3447743B2 (ja) 2003-09-16
CN1118573C (zh) 2003-08-20
JP2004290199A (ja) 2004-10-21
FI118224B (fi) 2007-08-31
PL181881B1 (pl) 2001-09-28
JP2005333990A (ja) 2005-12-08
JPH10501687A (ja) 1998-02-17
DE69524415D1 (de) 2002-01-17
EP0769056B1 (en) 2001-12-05
DE69524415T2 (de) 2002-08-01
CZ292283B6 (cs) 2003-08-13
TW496897B (en) 2002-08-01
FI20075338A (fi) 2007-05-10
MY114769A (en) 2003-01-31
JP4317786B2 (ja) 2009-08-19
LV11803A (lv) 1997-06-20
US5824508A (en) 1998-10-20
CZ305496A3 (en) 1997-10-15
US6054130A (en) 2000-04-25
NO964431L (no) 1996-12-11
KR100380953B1 (ko) 2003-10-10
AU707837B2 (en) 1999-07-22
JP2003230396A (ja) 2003-08-19
SK134396A3 (en) 1997-06-04
HU221647B1 (hu) 2002-12-28

Similar Documents

Publication Publication Date Title
EP0139417B1 (en) Vaccines based on membrane bound proteins and process for making them
Robbins et al. Pseudorabies virus gene encoding glycoprotein gIII is not essential for growth in tissue culture
US6207168B1 (en) Vaccine composition for herpes simplex virus and methods of using
JP2005333990A (ja) ｇｐ３５０／２２０非スプライシング変異体
Bowles et al. The ICP0 protein of equine herpesvirus 1 is an early protein that independently transactivates expression of all classes of viral promoters
US20130064844A1 (en) Non-splicing variants of gp350/220
US5807557A (en) Soluble herpesvirus glycoprotein complex
US6713296B1 (en) VZV gene, mutant VZV and immunogenic compositions
WO1998015289A9 (en) Proteins of kaposi's sarcoma associated herpesvirus
AU681131B2 (en) Recombinant epstein-barr virus protein and its use in vaccine